Cargando…
Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777635/ https://www.ncbi.nlm.nih.gov/pubmed/31686870 http://dx.doi.org/10.2147/IDR.S222943 |
_version_ | 1783456647608270848 |
---|---|
author | Cao, Zhimin Lan, Yuanbo Chen, Ling Xiang, Min Peng, Zhiyuan Zhang, Jianyong Zhang, Hong |
author_facet | Cao, Zhimin Lan, Yuanbo Chen, Ling Xiang, Min Peng, Zhiyuan Zhang, Jianyong Zhang, Hong |
author_sort | Cao, Zhimin |
collection | PubMed |
description | BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of Mycobacterium tuberculosis. PATIENTS AND METHODS: M. tuberculosis clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the pncA gene. RESULTS: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a pncA mutation, and 52 types of pncA mutations were detected from 64 isolates. The prevalence of pncA mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB. CONCLUSION: High prevalence of pncA mutations in clinical isolates of M. tuberculosis from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases. |
format | Online Article Text |
id | pubmed-6777635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67776352019-11-04 Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China Cao, Zhimin Lan, Yuanbo Chen, Ling Xiang, Min Peng, Zhiyuan Zhang, Jianyong Zhang, Hong Infect Drug Resist Original Research BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of Mycobacterium tuberculosis. PATIENTS AND METHODS: M. tuberculosis clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the pncA gene. RESULTS: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a pncA mutation, and 52 types of pncA mutations were detected from 64 isolates. The prevalence of pncA mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB. CONCLUSION: High prevalence of pncA mutations in clinical isolates of M. tuberculosis from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases. Dove 2019-09-30 /pmc/articles/PMC6777635/ /pubmed/31686870 http://dx.doi.org/10.2147/IDR.S222943 Text en © 2019 Cao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Cao, Zhimin Lan, Yuanbo Chen, Ling Xiang, Min Peng, Zhiyuan Zhang, Jianyong Zhang, Hong Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title | Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title_full | Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title_fullStr | Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title_full_unstemmed | Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title_short | Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China |
title_sort | resistance to first-line antituberculosis drugs and prevalence of pnca mutations in clinical isolates of mycobacterium tuberculosis from zunyi, guizhou province of china |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777635/ https://www.ncbi.nlm.nih.gov/pubmed/31686870 http://dx.doi.org/10.2147/IDR.S222943 |
work_keys_str_mv | AT caozhimin resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT lanyuanbo resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT chenling resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT xiangmin resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT pengzhiyuan resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT zhangjianyong resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina AT zhanghong resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina |